Kite Pharma Archives - Pharmaphorum

Gilead swoops to buy Kite for $12billion

August 28, 2017

Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.

Gilead swoops to buy Kite for $12billion

https://pharmaphorum.com/news/gilead-swoops-buy-kite-12billion/

Real world data essential for CAR-T therapy success

August 14, 2017

Innovators will need to quantify value to bring costly drugs to market.

Real world data essential for CAR-T therapy success

https://pharmaphorum.com/news/real-world-data-car-t/

Scottish firm gets EU funding for ‘off the shelf’ cancer cell therapy

August 3, 2017

First patients could be treated in 2019.

Scottish firm gets EU funding for ‘off the shelf’ cancer cell therapy

https://pharmaphorum.com/news/tcb-funding-off-shelf-cancer-therapy/

Kite files CAR-T therapy in EU, ahead of Novartis rival

August 1, 2017

Kite eyes possible CAR-T launch next year.

Kite files CAR-T therapy in EU, ahead of Novartis rival

https://pharmaphorum.com/news/kite-car-t-novartis/

New 3-year data supports Kite ‘cure’ hopes for CAR-T

July 21, 2017

A handful of patients with aggressive leukaemia appeared to have been cured thanks to CAR-T therapy, with some

New 3-year data supports Kite ‘cure’ hopes for CAR-T

https://pharmaphorum.com/news/new-3-year-data-supports-kite-cure-hopes-car-t/

Novartis close to first-ever CAR-T approval after unanimous vote

July 13, 2017

Panel unanimously back CTL019

Novartis close to first-ever CAR-T approval after unanimous vote

https://pharmaphorum.com/news/novartis-car-t-ctl019-backed-fda-advisers/

Novartis CAR-T safety in FDA spotlight

July 11, 2017

FDA advisers are set to make recommendations on Novartis’ groundbreaking CAR-T therapy CTL019 tomorrow – and are set to

Novartis CAR-T safety in FDA spotlight

https://pharmaphorum.com/news/fda-advisers-consider-novartis-car-t-safety/

Oxford BioMedica signs $100m CAR-T deal with Novartis

July 7, 2017

UK firm to supply viruses to generate CAR-T therapies

Oxford BioMedica signs $100m CAR-T deal with Novartis

https://pharmaphorum.com/news/oxford-biomedica-signs-100m-car-t-deal-novartis/

FDA to review Novartis CAR-T next month

June 6, 2017

If all goes well, FDA could approve CTL109 by late September

FDA to review Novartis CAR-T next month

https://pharmaphorum.com/news/novartis-facing-fda-panel-car-t/

Trending

Kite Pharma

Gilead swoops to buy Kite for $12billion

Real world data essential for CAR-T therapy success

Scottish firm gets EU funding for ‘off the shelf’ cancer cell therapy

Kite files CAR-T therapy in EU, ahead of Novartis rival

New 3-year data supports Kite ‘cure’ hopes for CAR-T

Novartis close to first-ever CAR-T approval after unanimous vote

Novartis CAR-T safety in FDA spotlight

Oxford BioMedica signs $100m CAR-T deal with Novartis

FDA to review Novartis CAR-T next month

CDD for Biologics Summit 2017

Neoantigen Summit 2017

ICI Summit Europe 2017

2nd Annual Cancer Immunotherapy Summit

6th International GMP, GCP & Quality Control Summit

Inhalation and Respiratory Drug Products Summit

NHS seal of approval for gestational diabetes app

Sanofi showcases eczema data ahead of EU decision

COPD triple approved, can GSK maximise its revenues?

Teva sells women’s health division to tackle $35bn debts

EU regulators reject Santhera’s Raxone for DMD

What is ‘affordable’? The reality of the PPRS

UK biotech round-up: Autolus joins CAR-T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit

Get real: virtual reality for healthcare comes of age

Unstable and unpredictable? The reality of the PPRS

Clinical trial summaries for lay people – unpicking the guidance

Search

Advanced Search

Trending

Kite Pharma